3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

Professional with Extensive Experience in Biotechnology Companies

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacture of biologics appoints a new member to the with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director.

José Luis Bartolomé has a solid profile in equipment and operations management and joins 3P Biopharmaceuticals with the aim of improving the company’s internal processes.

José Luis comes to 3P with more than 30 years of experience in the biotechnology sector. He has a degree in biology from Santiago de Compostela University and throughout his extensive experience has worked in different biotechnology companies.

His professional career began in 1986 at Cooper Zeltia, and later he worked in the production department of companies such as Wellcome-Biofarma, Glaxo, Genentech and Lonza, in all of which he was a Production Manager. Before joining the 3P team, he was General Manager at Laboratorios Ovejero.

Therefore, his professional career has been developed in GMP environments, and he is an expert in the implementation of technology transfers, as well as working in facilities and processes subject to continuous customer audits or by different regulatory authorities (FDA, AEMPS, etc.)

cGMP manufacture of biologics

 

I appreciate the confidence 3P has shown me by giving me the opportunity to work with such a highly qualified team. I hope to contribute my experience in leading biotechnology companies to achieve excellence through continuous improvement“, explained Bartolomé.

Dámaso Molero, CEO at 3P Biopharmaceuticals said: “it is a pleasure to welcome José Luis to 3P and to incorporate such an experienced profile into our management team. I am sure that his arrival will give a boost to 3P in many aspects.

With my previous experience I hope to help analyze situations and processes that can be modified for our clients greater satisfaction and confidence, as well as strengthen 3P to optimize employee development and their professional growth, added Bartolomé.

Therefore, with this new addition to the management team, 3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.

Our dedicated team of specialists will be happy to discuss any of your CDMO requirements. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.
Read more

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.
Read more

Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.